

**AUROBINDO PHARMA LIMITED**  
(CIN - L24239TG1986PLC015190)

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad - 500 038, India

Tel: +91 040 23736370 ; Fax: +91 40 23747340 ; Email: info@aurobindo.com

( Rs. In lakhs)

**STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER ENDED 30.06.2017**

	Quarter ended			Year ended
	30.06.2017	31.03.2017	30.06.2016	31.03.2017
	Unaudited	Audited (Refer note 3)	Unaudited	Audited
<b>1 Revenue from operations</b>				
(a) Net sales/income from operations (Inclusive of excise duty)	213,178	236,139	236,841	953,936
(b) Other operating income	5,651	5,870	6,118	24,185
<b>Total revenue from operations (inclusive of excise duty)</b>	<b>218,829</b>	<b>242,009</b>	<b>242,959</b>	<b>978,121</b>
<b>2 Other Income</b>				
(a) Foreign exchange gain	2,499	2,925	1,112	9,893
(b) Others	551	2,197	978	3,702
<b>Total other income</b>	<b>3,050</b>	<b>5,122</b>	<b>2,090</b>	<b>13,595</b>
<b>Total income (1+2)</b>	<b>221,879</b>	<b>247,131</b>	<b>245,049</b>	<b>991,716</b>
<b>3 Expenses</b>				
(a) Cost of material consumed	119,790	111,978	112,231	460,419
(b) Purchase of stock-in-trade	110	500	119	1,121
(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	(21,597)	52	5,809	3,132
(d) Employee benefits expense	25,976	25,250	22,454	92,730
(e) Finance costs	1,025	906	1,397	4,516
(f) Foreign exchange Loss (refer note 8 )	1,883	-	-	-
(g) Depreciation and amortisation expense	8,339	7,338	7,040	28,617
(h) Other expenses	45,691	46,230	45,697	183,324
<b>Total expenses</b>	<b>181,217</b>	<b>192,254</b>	<b>194,747</b>	<b>773,859</b>
<b>4 Profit before tax (1+2-3)</b>	<b>40,662</b>	<b>54,877</b>	<b>50,302</b>	<b>217,857</b>
<b>5 Tax expense</b>	<b>9,929</b>	<b>9,331</b>	<b>11,199</b>	<b>47,181</b>
<b>6 Profit for the period (4-5)</b>	<b>30,733</b>	<b>45,546</b>	<b>39,103</b>	<b>170,676</b>
<b>7 Other Comprehensive income/(expense) - items that will not be reclassified to profit or loss (net of tax)</b>	<b>(154)</b>	<b>30</b>	<b>(36)</b>	<b>(561)</b>
<b>8 Total Comprehensive income for the period (6+7)</b>	<b>30,579</b>	<b>45,576</b>	<b>39,067</b>	<b>170,115</b>
<b>9 Paid-up equity share capital (face value Re. 1 per share)</b>	<b>5,859</b>	<b>5,859</b>	<b>5,852</b>	<b>5,859</b>
<b>10 Earnings per equity share of Re.1/- each (not annualised)</b>				
(a) Basic	5.25	7.78	6.68	29.16
(a) Diluted	5.25	7.78	6.67	29.16

**NOTES:**

- The financial results of the Company has been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder.
- The above standalone financial results as reviewed by the audit committee have been approved by board of directors at its meeting held on August 9, 2017.
- The figures for the quarter ended March 31, 2017 are the balancing figures between audited figures in respect of the full financial year upto March 31, 2017 and the unaudited published year to date figures upto December 31, 2016, being the date of the end of the third quarter of the financial year, which have been subjected to a limited review by the statutory auditors.
- The Company's operates in only one segment viz. 'Pharmaceutical Products'.
- Exports of stand alone for current quarter is Rs.184,401 lakhs (June 30, 2016 Rs.201,825 lakhs).
- During the current quarter (i) Aurobindo Pharma Saudi Arabia Limited, a step down subsidiary was incorporated w.e.f May 8, 2017, (ii) AuroLogistics LLC, a step down subsidiary was incorporated w.e.f April 28, 2017 (iii) The name of Aurobindo Antibiotics Limited, a subsidiary has been changed to Raidurgam Developers Limited w.e.f July 7, 2017.
- During the quarter, Agile Pharma B.V., a step down subsidiary of the Company acquired Generis Farmacêutica SA and its subsidiaries viz. (i) Mer Medicamentos, Portugal (ii) Generis Phar, Portugal (iii) Pharma APS, Portugal (iv) Generis Mozambique, Mozambique.
- Foreign exchange loss includes exchange difference arising from foreign currency borrowings to the extent that they are regarded as an adjustment to finance cost as per para 6(e) of "Ind AS 23" on Borrowing costs.
- Previous period figures have been regrouped/rearranged wherever considered necessary to conform to the current period presentation.

By Order of the Board

N.Govindarajan  
Managing Director

Place: Hyderabad  
Date : August 9, 2017

www.aurobindo.com



**Limited Review Report – Standalone Financial Results****Review Report to  
The Board of Directors  
Aurobindo Pharma Limited**

We have reviewed the accompanying statement of unaudited standalone financial results of Aurobindo Pharma Limited (the 'Company') for the quarter ended June 30, 2017 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.


The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (Ind AS 34) prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of Companies (Indian Accounting Standards) Rules, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, is the responsibility of the Company's management and has been approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For S.R. BATLIBOI & ASSOCIATES LLP**

Chartered Accountants

**ICAI Firm registration number: 101049W/E300004****per Vikas Kumar Pansari**  
Partner

Membership No.: 93649



Place: Hyderabad

Date: August 9, 2017

**AUROBINDO PHARMA LIMITED**  
(CIN - L24239TG1986PLC015190)

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad - 500 038, India

Tel: +91 040 23736370 ; Fax: +91 40 23747340 ; Email: info@aurobindo.com

(Rs. In lakhs)

**STATEMENT OF CONSOLIDATED UNAUDITED RESULTS FOR THE QUARTER ENDED 30.06.2017**

	Quarter ended			Year ended
	30.06.2017	31.03.2017	30.06.2016	31.03.2017
	Unaudited	Audited (Refer note 4)	Unaudited	Audited
<b>1 Revenue from operations</b>				
(a) Net sales/income from operations (Inclusive of excise duty)	362,107	358,213	370,460	1,484,479
(b) Other operating income	5,768	5,950	6,199	24,507
<b>Total revenue from operations (inclusive of excise duty)</b>	<b>367,875</b>	<b>364,163</b>	<b>376,659</b>	<b>1,508,986</b>
<b>2 Other Income</b>				
(a) Foreign exchange gain	1,117	1,903	704	6,205
(b) Others	2,209	2,175	1,589	5,384
<b>Total other income</b>	<b>3,326</b>	<b>4,078</b>	<b>2,293</b>	<b>11,589</b>
<b>Total income (1+2)</b>	<b>371,201</b>	<b>368,241</b>	<b>378,952</b>	<b>1,520,575</b>
<b>3 Expenses</b>				
(a) Cost of material consumed	137,833	127,942	127,516	518,492
(b) Purchase of stock-in-trade	34,041	34,769	40,894	155,854
(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	(22,091)	(12,430)	(4,713)	(30,920)
(d) Employee benefits expense	49,017	46,346	43,208	176,776
(e) Finance costs	1,687	1,428	2,064	6,672
(f) Foreign exchange Loss (refer note 8)	1,883	-	-	-
(g) Depreciation and amortisation expense	13,118	10,005	10,624	42,763
(h) Other expenses	84,915	95,412	80,858	345,356
<b>Total expenses</b>	<b>300,403</b>	<b>303,472</b>	<b>300,451</b>	<b>1,214,993</b>
<b>4 Profit before tax (1+2-3)</b>	<b>70,798</b>	<b>64,769</b>	<b>78,501</b>	<b>305,582</b>
<b>5 Share of profit/(loss) of joint venture</b>	<b>134</b>	<b>168</b>	<b>73</b>	<b>502</b>
<b>6 Profit/(Loss) from ordinary activities before tax (4+5)</b>	<b>70,932</b>	<b>64,937</b>	<b>78,574</b>	<b>306,084</b>
<b>7 Tax expense</b>	<b>19,099</b>	<b>11,715</b>	<b>20,084</b>	<b>75,964</b>
<b>8 Profit for the period (6-7)</b>	<b>51,833</b>	<b>53,222</b>	<b>58,490</b>	<b>230,120</b>
<b>9 Non controlling interest</b>	<b>(18)</b>	<b>(23)</b>	<b>(6)</b>	<b>(47)</b>
<b>10 Net profit/(Loss) after taxes and non controlling interest (8-9)</b>	<b>51,851</b>	<b>53,245</b>	<b>58,496</b>	<b>230,167</b>
<b>11 Other Comprehensive income/(expense) - items that will not be reclassified to profit or loss (net of tax)</b>	<b>(158)</b>	<b>40</b>	<b>(36)</b>	<b>(579)</b>
<b>12 Total Comprehensive income for the period (10+11)</b>	<b>51,693</b>	<b>53,285</b>	<b>58,460</b>	<b>229,588</b>
<b>13 Paid-up equity share capital (face value Re. 1 per share)</b>	<b>5,859</b>	<b>5,859</b>	<b>5,852</b>	<b>5,859</b>
<b>14 Earnings per equity share of Re.1/- each (not annualised)</b>				
(a) Basic	8.85	9.10	9.99	39.33
(a) Diluted	8.85	9.10	9.99	39.33

**NOTES:**

- The financial results of the Company has been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder.
- The above consolidated financial results have been prepared in accordance with principals and procedures as set out in the Ind AS 110 on "Consolidated financial statements" and Ind AS 28 on "Investment in Associate and Joint Venture" notified under section 133 of Companies Act, 2013 and Companies (Indian Accounting Standards) Rules, 2015, as amended.
- The above consolidated financial results as reviewed by the audit committee have been approved by board of directors at its meeting held on August 9, 2017.
- The figures for the quarter ended March 31, 2017 are the balancing figures between audited figures in respect of the full financial year upto March 31, 2017 and the unaudited published year to date figures upto December 31, 2016, being the date of the end of the third quarter of the financial year, which have been subjected to a limited review by the statutory auditors.
- The Company's operates in only one segment viz. 'Pharmaceutical Products'.
- During the current quarter (i) Aurobindo Pharma Saudi Arabia Limited, a step down subsidiary was incorporated w.e.f May 8, 2017, (ii) AuroLogistics LLC, a step down subsidiary was incorporated w.e.f April 28, 2017 (iii) The name of Aurobindo Antibiotics Limited, a subsidiary has been changed to Raidurgam Developers Limited w.e.f July 7, 2017.
- During the quarter, Agile Pharma B.V., a step down subsidiary of the Company acquired Generis Farmac utica SA and its subsidiaries viz. (i) Mer Medicamentos, Portugal (ii) Generis Phar, Portugal (iii) Pharma APS, Portugal (iv) Generis Mozambique, Mozambique. The above consolidated results for the current quarter ended June 30, 2017 includes the results of operations of the above entities from May 01, 2017. The corresponding figures for the previous periods are not comparable. The accounting for this business combination has been prepared on a provisional basis as new information regarding the identifiable assets and liabilities as at the acquisition date may arise during the measurement period, being no more than one year from the date of acquisition.
- Foreign exchange loss includes exchange difference arising from foreign currency borrowings to the extent that they are regarded as an adjustment to finance cost as per para 6(e) of "Ind AS 23" on Borrowing costs.
- Previous period figures have been regrouped/rearranged wherever considered necessary to conform to the current period presentation.

By Order of the Board

N.Govindarajan  
Managing Director

Place: Hyderabad  
Date : August 9, 2017

www.aurobindo.com



**Limited Review Report – Consolidated Financial Results****Review Report to  
The Board of Directors  
Aurobindo Pharma Limited**

1. We have reviewed the accompanying statement of unaudited consolidated financial results of Aurobindo Pharma Limited comprising Aurobindo Pharma Limited (the 'Company'), its subsidiaries (together referred to as 'the Group'), and its joint ventures, for the quarter ended June 30, 2017 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.
2. The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (Ind AS 34) prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of Companies (Indian Accounting Standards) Rules, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, is the responsibility of the Company's management and has been approved by the Board of Directors of the Company. Our responsibility is to issue express a conclusion on the Statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. We did not review the financial statements and other financial information, in respect of 10 subsidiaries, whose financial statements include total assets of Rs. 615,203 lakhs and net assets of Rs. 263,449 lakhs as at June 30, 2017, and total revenues of Rs. 178,402 lakhs for the quarter ended on that date. These financial statements and other financial information have been reviewed by other auditors, which financial statements, other financial information and auditor's reports have been furnished to us by the management. Our conclusion, in so far as it relates to the affairs of such subsidiaries is based solely on the report of other auditors. Our conclusion is not modified in respect of this matter.

Certain of these subsidiaries are located outside India whose financial statements and other financial information have been prepared in accordance with accounting principles generally accepted in their respective countries and which have been reviewed by other auditors under generally accepted auditing standards applicable in their respective countries. The Company's management has converted the financial statements of such subsidiaries located outside India from accounting principles generally accepted in their respective countries to accounting principles generally accepted in India. We have reviewed these conversion adjustments made by the Company's management. Our conclusion in so far as it relates to the balances and affairs of such subsidiaries located outside India is based on the report of other auditors and the conversion adjustments prepared by the management of the Company and reviewed by us.



# **S.R. BATLIBOI & ASSOCIATES LLP**


Chartered Accountants

5. Based on our review conducted as above and based on the consideration of the reports of other auditors on the unaudited separate quarterly financial results and on the other financial information of subsidiaries, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited consolidated financial results prepared in accordance with recognition and measurement principles laid down in the applicable Indian Accounting Standards specified under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For S.R. BATLIBOI & ASSOCIATES LLP**

Chartered Accountants

**ICAI Firm registration number: 101049W/E300004**



**per Vikas Kumar Pansari**

Partner

Membership No.: 93649



Place: Hyderabad

Date: August 9, 2017